Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study

Giammarco Mocci; Antonio Tursi; Giovanni Maconi; Giovanni Cataletti; Beatrice Mantia; Mariaelena Serio; Antonella Scarcelli; Cristiano Pagnini; Maria Giovanna Graziani; Maria Carla Di Paolo; Giuseppe Pranzo; Ileana Luppino; Pietro Paese; Walter Elisei; Rita Monterubbianesi; Roberto Faggiani; Antonio Ferronato; Barbara Perini; Edoardo Savarino; Francesca Maria Onidi; Laura Binaghi; Paolo Usai Satta; Elisa Schiavoni; Daniele Napolitano; Franco Scaldaferri; Daniela Pugliese; Roberta Pica; Andrea Cocco; Maddalena Zippi; Stefano Rodino; Ladislava Sebkova; Giulia Rocco; Carlotta Sacchi; Costantino Zampaletta; Federica Gaiani; Gianluigi De Angelis; Stefano Kayali; Libera Fanigliulo; Roberto Lorenzetti; Leonardo Allegretta; Stefano Scorza; Antonio Cuomo; Laura Donnarumma; Nicola Della Valle; Rodolfo Sacco; Giacomo Forti; Elisabetta Antonelli; Gabrio Bassotti; Chiara Iannelli; Francesco Luzza; Giovanni Aragona; Patrizia Perazzo; Angelo Lauria; Simona Piergallini; Raffaele Colucci; Maria Antonia Bianco; Costantino Meucci; Gianmarco Giorgetti; Valeria Clemente; Serafina Fiorella; Antonio Penna; Antonio De Medici; Marcello Picchio; Alfredo Papa

doi:10.1080/14712598.2023.2185510

Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study

Giammarco Mocci, Antonio Tursi, Giovanni Maconi, Giovanni Cataletti, Beatrice Mantia, Mariaelena Serio, Antonella Scarcelli, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Giuseppe Pranzo, Ileana Luppino, Pietro Paese, Walter Elisei, Rita Monterubbianesi, Roberto Faggiani, Antonio Ferronato, Barbara Perini, Edoardo Savarino, Francesca Maria OnidiLaura Binaghi, Paolo Usai Satta, Elisa Schiavoni, Daniele Napolitano, Franco Scaldaferri, Daniela Pugliese, Roberta Pica, Andrea Cocco, Maddalena Zippi, Stefano Rodino, Ladislava Sebkova, Giulia Rocco, Carlotta Sacchi, Costantino Zampaletta, Federica Gaiani, Gianluigi De Angelis, Stefano Kayali, Libera Fanigliulo, Roberto Lorenzetti, Leonardo Allegretta, Stefano Scorza, Antonio Cuomo, Laura Donnarumma, Nicola Della Valle, Rodolfo Sacco, Giacomo Forti, Elisabetta Antonelli, Gabrio Bassotti, Chiara Iannelli, Francesco Luzza, Giovanni Aragona, Patrizia Perazzo, Angelo Lauria, Simona Piergallini, Raffaele Colucci, Maria Antonia Bianco, Costantino Meucci, Gianmarco Giorgetti, Valeria Clemente, Serafina Fiorella, Antonio Penna, Antonio De Medici, Marcello Picchio, Alfredo Papa

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

BackgroundVedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.Research design and methods Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity. Achievement and maintenance of clinical remission during the follow-up, and safety were the primary endpoints.Results729 patients (475 with UC and 254 with CD), median follow-up of 18 (IQR 6-36) months, were enrolled. Clinical remission at the 6(th) month of treatment was achieved in 488 (66.9%) patients (74.4% in CD vs 62.9% in UC, p<0.002) while, during the follow-up, no difference was found (81.5% in the UC group and 81.5% pts in the CD group; p=0.537). The clinical remission at the 6(th) month of treatment (p=0.001) and being naive to biologics (p<0.0001) were significantly associated with prolonged clinical remission. The clinical response was significantly higher in UC (90.1%) vs CD (84.3%) (p=0.023), and surgery occurred more frequently in CD (1.9% in UC vs 5.1% in CD, p=0.016).ConclusionWe found differences when using VDZ in UC vs CD in real life. These parameters can help the physician predict this drug's longterm efficacy.

Lingua originale	English
pagine (da-a)	293-304
Numero di pagine	12
Rivista	Expert Opinion on Biological Therapy
Volume	23
DOI	https://doi.org/10.1080/14712598.2023.2185510
Stato di pubblicazione	Pubblicato - 2023

Keywords

Crohn’s disease
remission
safety
ulcerative colitis
vedolizumab

Accesso al documento

10.1080/14712598.2023.2185510

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Mocci, G., Tursi, A., Maconi, G., Cataletti, G., Mantia, B., Serio, M., Scarcelli, A., Pagnini, C., Graziani, M. G., Di Paolo, M. C., Pranzo, G., Luppino, I., Paese, P., Elisei, W., Monterubbianesi, R., Faggiani, R., Ferronato, A., Perini, B., Savarino, E., ... Papa, A. (2023). Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study. Expert Opinion on Biological Therapy, 23, 293-304. https://doi.org/10.1080/14712598.2023.2185510

@article{0634d1510dc34ceaa8b23c0b395b5399,

title = "Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study",

abstract = "BackgroundVedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.Research design and methods Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity. Achievement and maintenance of clinical remission during the follow-up, and safety were the primary endpoints.Results729 patients (475 with UC and 254 with CD), median follow-up of 18 (IQR 6-36) months, were enrolled. Clinical remission at the 6(th) month of treatment was achieved in 488 (66.9%) patients (74.4% in CD vs 62.9% in UC, p<0.002) while, during the follow-up, no difference was found (81.5% in the UC group and 81.5% pts in the CD group; p=0.537). The clinical remission at the 6(th) month of treatment (p=0.001) and being naive to biologics (p<0.0001) were significantly associated with prolonged clinical remission. The clinical response was significantly higher in UC (90.1%) vs CD (84.3%) (p=0.023), and surgery occurred more frequently in CD (1.9% in UC vs 5.1% in CD, p=0.016).ConclusionWe found differences when using VDZ in UC vs CD in real life. These parameters can help the physician predict this drug's longterm efficacy.",

keywords = "Crohn{\textquoteright}s disease, remission, safety, ulcerative colitis, vedolizumab, Crohn{\textquoteright}s disease, remission, safety, ulcerative colitis, vedolizumab",

author = "Giammarco Mocci and Antonio Tursi and Giovanni Maconi and Giovanni Cataletti and Beatrice Mantia and Mariaelena Serio and Antonella Scarcelli and Cristiano Pagnini and Graziani, {Maria Giovanna} and {Di Paolo}, {Maria Carla} and Giuseppe Pranzo and Ileana Luppino and Pietro Paese and Walter Elisei and Rita Monterubbianesi and Roberto Faggiani and Antonio Ferronato and Barbara Perini and Edoardo Savarino and Onidi, {Francesca Maria} and Laura Binaghi and {Usai Satta}, Paolo and Elisa Schiavoni and Daniele Napolitano and Franco Scaldaferri and Daniela Pugliese and Roberta Pica and Andrea Cocco and Maddalena Zippi and Stefano Rodino and Ladislava Sebkova and Giulia Rocco and Carlotta Sacchi and Costantino Zampaletta and Federica Gaiani and {De Angelis}, Gianluigi and Stefano Kayali and Libera Fanigliulo and Roberto Lorenzetti and Leonardo Allegretta and Stefano Scorza and Antonio Cuomo and Laura Donnarumma and {Della Valle}, Nicola and Rodolfo Sacco and Giacomo Forti and Elisabetta Antonelli and Gabrio Bassotti and Chiara Iannelli and Francesco Luzza and Giovanni Aragona and Patrizia Perazzo and Angelo Lauria and Simona Piergallini and Raffaele Colucci and Bianco, {Maria Antonia} and Costantino Meucci and Gianmarco Giorgetti and Valeria Clemente and Serafina Fiorella and Antonio Penna and {De Medici}, Antonio and Marcello Picchio and Alfredo Papa",

year = "2023",

doi = "10.1080/14712598.2023.2185510",

language = "English",

volume = "23",

pages = "293--304",

journal = "Expert Opinion on Biological Therapy",

issn = "1471-2598",

publisher = "Taylor and Francis Ltd.",

}

Mocci, G, Tursi, A, Maconi, G, Cataletti, G, Mantia, B, Serio, M, Scarcelli, A, Pagnini, C, Graziani, MG, Di Paolo, MC, Pranzo, G, Luppino, I, Paese, P, Elisei, W, Monterubbianesi, R, Faggiani, R, Ferronato, A, Perini, B, Savarino, E, Onidi, FM, Binaghi, L, Usai Satta, P, Schiavoni, E, Napolitano, D, Scaldaferri, F , Pugliese, D, Pica, R, Cocco, A, Zippi, M, Rodino, S, Sebkova, L, Rocco, G, Sacchi, C, Zampaletta, C, Gaiani, F, De Angelis, G, Kayali, S, Fanigliulo, L, Lorenzetti, R, Allegretta, L, Scorza, S, Cuomo, A, Donnarumma, L, Della Valle, N, Sacco, R, Forti, G, Antonelli, E, Bassotti, G, Iannelli, C, Luzza, F, Aragona, G, Perazzo, P, Lauria, A, Piergallini, S, Colucci, R, Bianco, MA, Meucci, C, Giorgetti, G, Clemente, V, Fiorella, S, Penna, A, De Medici, A, Picchio, M & Papa, A 2023, 'Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study', Expert Opinion on Biological Therapy, vol. 23, pagg. 293-304. https://doi.org/10.1080/14712598.2023.2185510

TY - JOUR

T1 - Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study

AU - Mocci, Giammarco

AU - Tursi, Antonio

AU - Maconi, Giovanni

AU - Cataletti, Giovanni

AU - Mantia, Beatrice

AU - Serio, Mariaelena

AU - Scarcelli, Antonella

AU - Pagnini, Cristiano

AU - Graziani, Maria Giovanna

AU - Di Paolo, Maria Carla

AU - Pranzo, Giuseppe

AU - Luppino, Ileana

AU - Paese, Pietro

AU - Elisei, Walter

AU - Monterubbianesi, Rita

AU - Faggiani, Roberto

AU - Ferronato, Antonio

AU - Perini, Barbara

AU - Savarino, Edoardo

AU - Onidi, Francesca Maria

AU - Binaghi, Laura

AU - Usai Satta, Paolo

AU - Schiavoni, Elisa

AU - Napolitano, Daniele

AU - Scaldaferri, Franco

AU - Pugliese, Daniela

AU - Pica, Roberta

AU - Cocco, Andrea

AU - Zippi, Maddalena

AU - Rodino, Stefano

AU - Sebkova, Ladislava

AU - Rocco, Giulia

AU - Sacchi, Carlotta

AU - Zampaletta, Costantino

AU - Gaiani, Federica

AU - De Angelis, Gianluigi

AU - Kayali, Stefano

AU - Fanigliulo, Libera

AU - Lorenzetti, Roberto

AU - Allegretta, Leonardo

AU - Scorza, Stefano

AU - Cuomo, Antonio

AU - Donnarumma, Laura

AU - Della Valle, Nicola

AU - Sacco, Rodolfo

AU - Forti, Giacomo

AU - Antonelli, Elisabetta

AU - Bassotti, Gabrio

AU - Iannelli, Chiara

AU - Luzza, Francesco

AU - Aragona, Giovanni

AU - Perazzo, Patrizia

AU - Lauria, Angelo

AU - Piergallini, Simona

AU - Colucci, Raffaele

AU - Bianco, Maria Antonia

AU - Meucci, Costantino

AU - Giorgetti, Gianmarco

AU - Clemente, Valeria

AU - Fiorella, Serafina

AU - Penna, Antonio

AU - De Medici, Antonio

AU - Picchio, Marcello

AU - Papa, Alfredo

PY - 2023

Y1 - 2023

N2 - BackgroundVedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.Research design and methods Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity. Achievement and maintenance of clinical remission during the follow-up, and safety were the primary endpoints.Results729 patients (475 with UC and 254 with CD), median follow-up of 18 (IQR 6-36) months, were enrolled. Clinical remission at the 6(th) month of treatment was achieved in 488 (66.9%) patients (74.4% in CD vs 62.9% in UC, p<0.002) while, during the follow-up, no difference was found (81.5% in the UC group and 81.5% pts in the CD group; p=0.537). The clinical remission at the 6(th) month of treatment (p=0.001) and being naive to biologics (p<0.0001) were significantly associated with prolonged clinical remission. The clinical response was significantly higher in UC (90.1%) vs CD (84.3%) (p=0.023), and surgery occurred more frequently in CD (1.9% in UC vs 5.1% in CD, p=0.016).ConclusionWe found differences when using VDZ in UC vs CD in real life. These parameters can help the physician predict this drug's longterm efficacy.

AB - BackgroundVedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.Research design and methods Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity. Achievement and maintenance of clinical remission during the follow-up, and safety were the primary endpoints.Results729 patients (475 with UC and 254 with CD), median follow-up of 18 (IQR 6-36) months, were enrolled. Clinical remission at the 6(th) month of treatment was achieved in 488 (66.9%) patients (74.4% in CD vs 62.9% in UC, p<0.002) while, during the follow-up, no difference was found (81.5% in the UC group and 81.5% pts in the CD group; p=0.537). The clinical remission at the 6(th) month of treatment (p=0.001) and being naive to biologics (p<0.0001) were significantly associated with prolonged clinical remission. The clinical response was significantly higher in UC (90.1%) vs CD (84.3%) (p=0.023), and surgery occurred more frequently in CD (1.9% in UC vs 5.1% in CD, p=0.016).ConclusionWe found differences when using VDZ in UC vs CD in real life. These parameters can help the physician predict this drug's longterm efficacy.

KW - Crohn’s disease

KW - remission

KW - safety

KW - ulcerative colitis

KW - vedolizumab

KW - Crohn’s disease

KW - remission

KW - safety

KW - ulcerative colitis

KW - vedolizumab

UR - http://hdl.handle.net/10807/231832

U2 - 10.1080/14712598.2023.2185510

DO - 10.1080/14712598.2023.2185510

M3 - Article

SN - 1471-2598

VL - 23

SP - 293

EP - 304

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

ER -

Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo